Phase 3 Study of Adjuvant Regorafenib vs. Placebo for Patients with Stage 4 colorectal cancer
What is the purpose of this trial?
The objective of this study is to evaluate and compare the efficacy and safety of regorafenib vs. placebo in subjects with colorectal cancer after curative resection of liver metastasis and completion of all planned chemotherapy.
- 18 Years and older
- Bayer Healthcare Pharmaceuticals, Inc.
- Last Updated:
- Study HIC#: